A Novel Protein Pathway Emerges as a Promising Target for Alzheimer’s Disease Treatment

Researchers at Johns Hopkins Medicine are embarking on a new frontier in the fight against Alzheimer’s disease, fueled by a substantial grant from the National Institutes of Health (NIH). This groundbreaking study is delving into the intricate workings of a protein within the brain that, despite its subtle influence, plays a critical role in cognitive function and memory formation. The protein, known as Cystathionine gamma-lyase (CSE), is primarily recognized for its production of hydrogen sulfide (H2S), a gas notorious for its pungent, rotten-egg odor. However, the latest findings suggest this malodorous compound may hold significant therapeutic potential for neurodegenerative conditions.

Unraveling the Role of Hydrogen Sulfide in Brain Health

The research, meticulously detailed in a recent publication in the prestigious journal Proceedings of the National Academy of Sciences, aims to illuminate the precise mechanisms by which CSE influences memory. The ultimate goal is to determine whether enhancing the activity of this protein could serve as a protective shield for brain cells, thereby slowing the relentless progression of devastating neurodegenerative diseases like Alzheimer’s.

Prior investigations have hinted at the neuroprotective capabilities of hydrogen sulfide in animal models. These studies demonstrated that H2S could indeed safeguard neurons. However, the inherent toxicity of the gas in higher concentrations presents a significant hurdle for direct therapeutic delivery to the brain. Consequently, the scientific community is now focused on understanding how to safely maintain the extremely low levels of H2S that are naturally and beneficially present within neurons.

Evidence from Genetically Engineered Mice

The current findings stem from extensive experiments conducted on genetically engineered mice, a critical component of the research led by Dr. Bindu Paul, an associate professor of pharmacology, psychiatry, and neuroscience at the Johns Hopkins University School of Medicine. These mice were specifically designed to lack the CSE enzyme. The results were stark: these CSE-deficient mice exhibited significant impairments in their ability to learn and retain memories. Furthermore, they displayed elevated levels of oxidative stress, a detrimental cellular process implicated in aging and disease; evident DNA damage; and compromised integrity of the blood-brain barrier. These physiological markers are all hallmarks commonly observed in individuals suffering from Alzheimer’s disease, as noted by Dr. Paul, who also serves as the study’s corresponding author.

A Legacy of Research Paves the Way

This latest research stands on the shoulders of years of dedicated investigation led by Dr. Solomon Snyder, a professor emeritus of neuroscience, pharmacology, and psychiatry at Johns Hopkins. His influential team first reported in 2014 that CSE played a supportive role in brain health, specifically in mice afflicted with Huntington’s disease. The development of CSE-deficient mice, which proved instrumental in these earlier studies, dates back to 2008 when the protein was first linked to crucial physiological functions, including blood vessel health and the regulation of blood pressure.

Building upon this foundation, the research group made a significant discovery in 2021. They observed that CSE was not functioning optimally in mice exhibiting Alzheimer’s-like pathology. Intriguingly, very low-dose injections of hydrogen sulfide were found to offer a degree of protection to brain function in these models. While those earlier studies involved mice with additional genetic mutations predisposing them to neurodegenerative conditions, the current research undertakes the critical task of isolating and examining the specific role of CSE itself, independent of other genetic factors.

"This most recent work indicates that CSE alone is a major player in cognitive function and could provide a new avenue for treatment pathways in Alzheimer’s disease," stated Dr. Snyder, a co-corresponding author on the study. Dr. Snyder, who retired from the Johns Hopkins Medicine faculty in 2023, continues to contribute his extensive expertise to this vital field.

Progressive Memory Deficits Linked to CSE Deficiency

To meticulously investigate the connection between CSE and memory, the researchers conducted a comparative analysis between normal mice and those engineered to lack the CSE protein, utilizing the same mouse strain developed in 2008. A key element of their methodology involved assessing spatial memory – the ability to recall directions and navigate environments – through a well-established behavioral test known as the Barnes maze.

In this experimental setup, mice are tasked with locating a hidden escape tunnel from a brightly lit arena. At two months of age, both the control group and the CSE-deficient mice demonstrated comparable proficiency, successfully finding the shelter within a three-minute timeframe. However, a significant divergence emerged by the six-month mark. The mice lacking CSE began to struggle considerably in locating the escape route, indicating a decline in their spatial memory capabilities. In contrast, the normal mice maintained their performance, consistently finding the shelter with ease.

"The decline in spatial memory indicates a progressive onset of neurodegenerative disease that we can attribute to CSE loss," explained Dr. Suwarna Chakraborty, the study’s first author and a researcher within Dr. Paul’s laboratory. This observation strongly suggests that the absence of CSE is not merely an incidental finding but a direct contributor to the cognitive deterioration observed.

Cellular and Structural Brain Changes Mimic Alzheimer’s Disease Pathology

Beyond behavioral assessments, the research team delved into the cellular and structural alterations occurring within the brains of CSE-deficient mice. The hippocampus, a brain region indispensable for learning and memory consolidation, relies heavily on the continuous generation of new neurons, a process known as neurogenesis. Disruptions in neurogenesis are a well-established characteristic of many neurodegenerative diseases, including Alzheimer’s.

Employing sophisticated biochemical and analytical techniques, the scientists discovered that the levels of proteins crucial for neurogenesis were significantly reduced or entirely absent in the brains of mice lacking CSE.

Further microscopic examination using high-powered electron microscopes revealed striking structural damage within the brains of these mice. The researchers identified substantial breaks in blood vessels, a clear indication of compromised blood-brain barrier integrity – another critical pathological feature associated with Alzheimer’s disease. Moreover, the study observed that newly formed neurons in these mice faced considerable difficulties in migrating to the hippocampus, where they are meant to integrate and contribute to memory formation.

"The mice lacking CSE were compromised at multiple levels, which correlated with symptoms that we see in Alzheimer’s disease," commented Dr. Sunil Jamuna Tripathi, a co-first author and researcher in Dr. Paul’s lab. This multi-faceted evidence paints a compelling picture of how CSE deficiency can directly contribute to a cascade of pathological events mirroring those seen in Alzheimer’s disease.

Implications for Future Alzheimer’s Therapies

Alzheimer’s disease represents a formidable public health challenge, affecting over 6 million individuals in the United States alone, with projections indicating a continued rise in prevalence according to the Centers for Disease Control and Prevention (CDC). Despite extensive research efforts, the current therapeutic landscape offers limited options, with no treatments consistently demonstrating the ability to halt or effectively slow the disease’s relentless progression.

The findings from Johns Hopkins Medicine offer a beacon of hope by identifying a novel therapeutic target. The researchers posit that interventions aimed at modulating CSE activity and, consequently, its production of hydrogen sulfide, could pave the way for the development of innovative therapies. Such treatments would be designed to bolster the brain’s natural defense mechanisms, protect vital neural circuits, and ultimately slow the debilitating cognitive decline associated with Alzheimer’s disease.

The implications of this research extend beyond Alzheimer’s, potentially impacting the treatment of other neurodegenerative disorders where oxidative stress and compromised blood-brain barrier function play significant roles. Understanding how to safely harness the protective power of hydrogen sulfide could revolutionize the management of a wide spectrum of neurological conditions.

Funding and Collaborative Efforts

This vital research was made possible through substantial funding from the National Institutes of Health (NIH), with specific grants including 1R01AG071512, P50 DA044123, 1R21AG073684, O1AGs066707, U01 AG073323, AG077396, NS101967, NS133688, and P01CA236778. Additional crucial support was provided by the Department of Defense (HT94252310443), the American Heart Association, the AHA-Allen Initiative in Brain Health and Cognitive Impairment, the Solve ME/CFS Initiative, the Catalyst Award from Johns Hopkins University, the Valour Foundation, the Wick Foundation, the Department of Veterans Affairs Merit Award (I01BX005976), the Louis Stokes Cleveland Department of Medical Affairs Veterans Center, the Mary Alice Smith Funds for Neuropsychiatry Research, the Lincoln Neurotherapeutics Research Fund, the Gordon and Evie Safran Neuropsychiatry Fund, and the Leonard Krieger Fund of the Cleveland Foundation.

The collaborative nature of this research is evident in the extensive list of contributors. Beyond Dr. Paul, Dr. Snyder, Dr. Chakraborty, and Dr. Tripathi from Johns Hopkins, the study involved Richa Tyagi and Benjamin Orsburn from Johns Hopkins; Edwin Vázquez-Rosa, Kalyani Chaubey, Hisashi Fujioka, Emiko Miller, and Andrew Pieper from Case Western University; Thibaut Vignane and Milos Filipovic from the Leibniz Institute for Analytical Sciences in Germany; Sudarshana Sharma from Hollings Cancer Center; Bobby Thomas from Darby Children’s Research Institute and the Medical University of South Carolina; and Zachary Weil and Randy Nelson from West Virginia University School of Medicine. This interdisciplinary approach underscores the complexity and significance of the research undertaken.

The ongoing exploration of CSE and hydrogen sulfide’s role in brain health represents a significant step forward in understanding and potentially treating Alzheimer’s disease. The findings provide a robust foundation for future therapeutic development, offering a glimmer of hope for millions affected by this devastating condition.